RNA Interference Therapeutics Market Size & Share 2026-2035

RNA Interference Therapeutics Market Size

The RNA interference (RNAi) therapeutics market was valued at USD 4.2 billion in 2025. The market is expected to grow from USD 6.8 billion in 2026 to USD 31.4 billion in 2035, at a CAGR of 18.5% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market growth is primarily driven by advancements in genetic research, increasing prevalence of rare genetic disorders, and the rising burden of chronic diseases worldwide. RNAi therapeutics have emerged as a transformative treatment modality by enabling targeted silencing of disease-causing genes, thereby addressing significant unmet medical needs in conditions such as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and hypercholesterolemia.

RNAi therapeutics represent a novel class of gene-silencing drugs that utilize small interfering RNA (siRNA) molecules to selectively inhibit gene expression through degradation of target messenger RNA (mRNA). These therapies offer highly specific molecular targeting and are increasingly being explored for the treatment of genetic, metabolic, cardiovascular, hepatic, and other rare diseases. The development of advanced delivery technologies, including lipid nanoparticles (LNPs) and N-acetylgalactosamine (GalNAc) conjugates, has significantly enhanced the clinical viability and commercial potential of RNAi-based medicines.

Technological advancements in RNAi delivery platforms have played a pivotal role in market expansion. Improved tissue-specific targeting, enhanced drug stability, and reduced off-target effects have strengthened the efficacy and safety profile of RNAi therapeutics, supporting broader clinical adoption. These innovations have also encouraged strategic collaborations, licensing agreements, and investment activities among biotechnology companies and pharmaceutical manufacturers, accelerating the development and commercialization of next-generation RNAi therapies.

The market has witnessed substantial growth over recent years, supported by increasing regulatory acceptance of RNA-based medicines and a growing pipeline of clinical-stage candidates. Furthermore, the integration of RNAi technologies with emerging therapeutic approaches, including gene editing and antisense oligonucleotide (ASO) therapies, is creating new opportunities for precision medicine applications. The adoption of artificial intelligence (AI) and machine learning in drug discovery is further streamlining siRNA design, target identification, and efficacy optimization, thereby reducing development timelines and enhancing success rates.

Key factors driving market growth include the increasing focus on personalized medicine, rising incidence of chronic liver, metabolic, and cardiovascular disorders, and growing investment in innovative gene-based therapeutics. Additionally, favorable regulatory pathways for orphan drugs and rare disease treatments, including expedited review programs and market exclusivity benefits, continue to support the commercialization of RNAi products. As scientific understanding of gene silencing mechanisms advances and the therapeutic pipeline diversifies, RNAi therapeutics are expected to play an increasingly important role in the future landscape of precision medicine and targeted disease management.

RNA Interference Therapeutics Market Trends

• The RNAi therapeutics market is transitioning from a research-driven domain to a commercially viable therapeutic segment, supported by advancements in delivery technologies, favorable regulatory developments, and increasing investments in RNA-based research from government agencies, academic institutions, and industry stakeholders.
• As of 2025, the U.S. Food and Drug Administration (FDA) has approved 21 RNA-based therapeutics, including 8 RNAi therapies, highlighting the growing clinical and commercial acceptance of gene-silencing technologies. These approvals demonstrate the ability of RNAi therapeutics to address diseases with limited treatment options. Furthermore, approximately 48 ongoing clinical trials involving RNAi-based candidates reflect strong momentum in research and product development activities across multiple therapeutic areas.
• Small interfering RNA (siRNA) remains the dominant technology within the RNAi landscape owing to its high target specificity and compatibility with advanced delivery platforms. Innovations such as GalNAc conjugates for targeted liver delivery and lipid nanoparticle (LNP) systems for systemic administration have improved therapeutic efficacy, enhanced tissue targeting, and reduced off-target effects. While early RNAi development primarily focused on liver-related diseases, the technology is increasingly being applied to cardiovascular, oncology, neurological, metabolic, and other complex disorders.
• Public-sector support continues to play a critical role in market development. Government-funded research programs and academic initiatives have accelerated early-stage innovation, strengthened translational research efforts, and facilitated collaborations between research institutions and biopharmaceutical companies.
• The integration of artificial intelligence (AI) and machine learning technologies is further accelerating RNAi drug discovery and development. AI-enabled platforms are helping researchers optimize siRNA sequence design, improve target selection, reduce off-target interactions, and enhance delivery efficiency. Simultaneously, contract development and manufacturing organizations (CDMOs) are expanding their oligonucleotide development and manufacturing capabilities to meet the growing demand for RNA-based therapeutics.
• North America currently represents the largest market for RNAi therapeutics, supported by a strong biotechnology ecosystem, significant research funding, and a favorable regulatory environment. However, the Asia-Pacific region is emerging as a high-growth market due to increasing biotechnology investments, expanding clinical trial activity, and evolving regulatory frameworks. The combination of clinical validation, technological innovation, and institutional support is positioning RNAi therapeutics as a key pillar of the future precision medicine landscape

RNA Interference Therapeutics Market Analysis

Based on indication, the global RNA interference therapeutics market is divided into hereditary transthyretin-mediated amyloidosis (hATTR), transthyretin amyloidosis with cardiomyopathy (ATTR-CM), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), hypercholesterolemia / dyslipidemia, hemophilia A and B, and familial chylomicronemia syndrome (FCS). The hATTR segment accounted for 35.7% of the market in 2025. The segment is expected to exceed USD 10.9 billion by 2035, growing at a CAGR of 18.2% during the forecast period.    

• Hereditary transthyretin-mediated amyloidosis (hATTR) remains the leading indication in the RNAi therapeutics market, driven by the availability of commercially approved siRNA-based therapies and growing rates of disease diagnosis. hATTR is a rare inherited disorder characterized by mutations in the transthyretin (TTR) gene, resulting in amyloid protein deposition in peripheral nerves, cardiac tissue, and other organs, leading to progressive multisystem complications.
• The segment has benefited significantly from the commercialization of RNAi therapies such as Onpattro and Amvuttra, which suppress TTR protein production by targeting TTR mRNA in the liver. Increasing physician awareness, broader adoption of genetic testing, and expanding access to specialized treatment centers continue to support market growth. Moreover, the availability of disease-modifying therapies has improved treatment outcomes and accelerated patient uptake.
• According to estimates from rare disease organizations, hATTR affects approximately 50,000 individuals worldwide. Advances in genetic screening and earlier diagnosis are expected to increase the eligible patient population, thereby strengthening long-term demand for RNAi-based treatments.
• On the other hand, the ATTR-CM segment is anticipated to register the fastest growth, with a projected CAGR of 19.2% over the forecast period. Rising recognition of cardiac amyloidosis, an expanding elderly population, and recent regulatory approvals of RNAi therapies for ATTR-CM are key factors driving growth. Improved cardiac imaging techniques, enhanced disease awareness among cardiologists, and growing adoption of precision medicine approaches are further contributing to segment expansion.   

Based on route of administration, the RNA interference therapeutics market is classified into intravenous (IV), and subcutaneous (SC). The SC segment dominated the market in 2025 and is growing with a CAGR of 18.6% during the forecast period.

• Subcutaneous administration has emerged as the preferred delivery route for RNAi therapeutics due to its convenience, improved patient compliance, and reduced treatment burden compared with intravenous infusion. The widespread adoption of GalNAc-conjugated siRNA technologies has been instrumental in driving this trend, enabling targeted delivery to hepatocytes through simple subcutaneous injections.
• This targeted delivery approach enhances therapeutic efficacy while minimizing systemic exposure and adverse effects. Several commercially successful RNAi therapies, including inclisiran and lumasiran, have validated the effectiveness of subcutaneous administration, contributing to its growing acceptance among healthcare providers and patients.
• In addition, SC administration facilitates outpatient treatment, reduces hospital dependency, and lowers healthcare resource utilization, making it an increasingly attractive option for long-term disease management.
• The intravenous (IV) segment was valued at USD 172.8 million in 2025 and continues to play a critical role in the administration of certain RNAi therapies. Early-generation RNAi products and therapies requiring rapid systemic distribution often rely on infusion-based delivery to achieve optimal therapeutic outcomes.
• Intravenous administration remains essential for products such as patisiran, where controlled dosing and systemic exposure are critical. The segment also benefits from established infusion infrastructure across hospitals and specialty care facilities, as well as ongoing clinical development of RNAi therapies targeting complex and severe disease indications.

Based on end use, RNA interference therapeutics market is classified into hospitals, specialty treatment centers, and clinics. The hospitals segment dominated the market in 2025 and is expected to reach USD 15.8 billion by 2035.     

• Hospitals constitute the primary end-use setting for RNAi therapeutics due to their advanced diagnostic capabilities, specialized treatment infrastructure, and access to multidisciplinary healthcare teams. The management of rare genetic, metabolic, cardiovascular, and hepatic disorders often requires coordinated care involving neurologists, cardiologists, hepatologists, genetic counselors, and other specialists, which is readily available in hospital settings.
• Several approved RNAi therapies, including Onpattro, require administration and monitoring within hospital environments, while therapies such as Leqvio and Amvuttra are frequently prescribed and managed by hospital-affiliated specialists. The increasing establishment of rare disease centers of excellence and expansion of infusion facilities are further strengthening hospital demand.
• Growing adoption of precision medicine, wider availability of genetic testing services, and favorable reimbursement policies for high-cost innovative therapies are also contributing to increased patient volumes and treatment uptake across hospitals worldwide.
• Specialty treatment centers represent the second-largest end-use segment and were valued at USD 1.3 billion in 2025. Growth in this segment is driven by rising demand for specialized care for rare disorders such as hATTR and acute hepatic porphyria (AHP).
• These centers offer disease-specific expertise, personalized treatment protocols, infusion services, patient education programs, and long-term follow-up capabilities, making them well-positioned to support the administration and monitoring of RNAi therapeutics. As the number of approved RNAi therapies expands, specialty centers are expected to play an increasingly important role in improving patient access and treatment outcomes.

North America RNA interference therapeutics market

The North America market dominated the global market with a market share of 72% in 2025.  

• The region has been at the forefront of RNAi commercialization, supported by the successful launch and uptake of approved therapies such as Onpattro, Leqvio, Amvuttra, and Givlaari. Strong regulatory support and established pathways for orphan and rare disease therapies have accelerated market penetration and product development.
• North America benefits from a robust biotechnology landscape, led by companies such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, alongside a growing network of research institutions and clinical centers focused on RNA-based therapeutics. Continuous investments in next-generation delivery technologies, including GalNAc conjugates and lipid nanoparticle (LNP) platforms, are expanding the therapeutic scope of RNAi beyond liver-targeted diseases.
• Increasing adoption of precision medicine, growing utilization of genetic testing, and improved diagnosis of rare hereditary disorders continue to support demand. In addition, the presence of specialized centers for amyloidosis, metabolic diseases, and cardiovascular disorders has enhanced patient access to advanced RNAi therapies.

The U.S. RNA interference therapeutics market was valued at USD 575.9 million and USD 898.7 million in 2022 and 2023, respectively. The market size reached USD 2.9 billion in 2025, growing from USD 1.4 billion in 2024. 

• The U.S. remains the largest contributor to regional revenue, driven by its strong biotechnology sector, extensive clinical research activity, and leadership in genomic medicine. The country accounts for a substantial share of global RNAi clinical trials and continues to attract significant investment in RNA-based drug development.
• Growing prevalence of cardiometabolic disorders, hereditary diseases, and rare genetic conditions is expanding the addressable patient population. Increasing awareness of genetic screening and earlier diagnosis are further supporting treatment adoption.
• The U.S. also benefits from strong collaboration among pharmaceutical companies, academic research centers, and government-funded institutions, creating a favorable environment for innovation and commercialization of RNAi therapeutics. Ongoing pipeline expansion into cardiovascular, neurological, and metabolic diseases is expected to sustain long-term market growth.

Europe RNA interference therapeutics market

Europe market accounted for USD 714.8 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe has emerged as an important market for RNAi therapeutics, supported by increasing investment in precision medicine, strong academic research capabilities, and a favorable regulatory environment for advanced therapies. The region has demonstrated growing acceptance of RNA-based medicines, particularly for rare and genetically inherited disorders.
• The presence of established healthcare systems and comprehensive rare disease management programs has facilitated access to innovative therapies across major European countries. Increasing adoption of genetic diagnostics and personalized treatment approaches is further strengthening market demand.
• Collaborative research initiatives involving universities, biotechnology companies, and clinical research organizations have accelerated innovation in RNA therapeutics. Furthermore, rising healthcare expenditure and continued investments in orphan disease research are fostering the development and commercialization of novel RNAi treatments.

Germany dominates the European RNA interference therapeutics market, showcasing strong growth potential.

• The country benefits from one of the strongest biotechnology and pharmaceutical ecosystems in Europe, supported by advanced healthcare infrastructure and a highly active clinical research environment.
• Germany has established itself as a key hub for RNA-based innovation, with significant participation in clinical trials evaluating novel RNAi therapies. Strong partnerships between academic institutions, healthcare providers, and global pharmaceutical companies continue to accelerate product development and clinical adoption.
• Government support for rare disease research, coupled with increasing emphasis on personalized medicine and genomic healthcare, is expected to further strengthen Germany's position as a leading market for RNAi therapeutics in Europe.

Asia Pacific RNA interference therapeutics market

The Asia Pacific market is anticipated to grow at the highest CAGR of 18.8% during the analysis timeframe.

• Asia Pacific is rapidly emerging as a strategic growth region due to increasing investments in biotechnology, expanding healthcare infrastructure, and growing adoption of genomic and precision medicine technologies. Governments across the region are actively supporting advanced biopharmaceutical research through funding programs, innovation initiatives, and regulatory reforms.
• Rising prevalence of cardiovascular, metabolic, and rare genetic diseases is creating significant opportunities for RNAi-based therapies. In parallel, improving awareness of genetic disorders and increasing availability of advanced diagnostic technologies are enhancing patient identification and treatment rates.
• The region is also becoming an important destination for clinical research, supported by large patient populations, improving research capabilities, and increasing participation in multinational clinical trials. Countries such as China, Japan, South Korea, and India are playing a central role in expanding the regional RNA therapeutics ecosystem. 

China RNA interference therapeutics market is estimated to grow with a significant CAGR, in the Asia Pacific market.  

• The country's growth is driven by substantial investments in biotechnology innovation, expanding domestic pharmaceutical capabilities, and strong government support for advanced therapeutic development. Chinese biotechnology companies are increasingly focusing on RNA-based drug discovery and are actively building proprietary RNAi pipelines.
• China has become a major center for clinical research in RNA therapeutics, with growing participation in global clinical trials and strategic collaborations between domestic companies and multinational pharmaceutical organizations. Regulatory reforms aimed at accelerating approval timelines for innovative medicines have further improved the market outlook.
• The country's large patient population, rising healthcare expenditure, and increasing focus on precision medicine provide significant commercial opportunities for RNAi therapeutics. As local research capabilities continue to mature, China is expected to play an increasingly influential role in the global development, manufacturing, and commercialization of RNA-based therapies.

RNA Interference Therapeutics Market Share

The RNAi therapeutics market features a dynamic and moderately consolidated competitive landscape, shaped by a mix of established biopharmaceutical companies, RNA-focused biotech firms, and emerging RNA platform innovators. Leading players such as Alnylam Pharmaceuticals, Novartis, Novo Nordisk, Sanofi, and Arrowhead Pharmaceuticals collectively account for a 100% market share, driven by robust pipelines, strategic licensing agreements, and first-to-market RNAi drug approvals.  

To strengthen their market position, these companies are leveraging multi-pronged strategies, including strategic alliances with big pharma, co-development deals, expansion of GalNAc and LNP delivery platforms, and geographic market penetration. Their focus remains on advancing RNAi drugs for rare genetic diseases, cardiometabolic disorders, and hepatic conditions, while integrating AI in drug design and delivery optimization.

Emerging players are contributing through innovations in non-hepatic delivery systems, extrahepatic targeting, and scalable manufacturing. Their growing presence is particularly evident in Asia-Pacific, Europe, and the Middle East, where increasing genomic research, government funding, and biotech infrastructure are accelerating RNAi therapeutic development and adoption.

RNA Interference Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• Commercial players
  • Alnylam Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Sanofi
  • Arrowhead Pharmaceuticals
• Emerging pipeline players
  • Silence Therapeutics
  • Sirnaomics
  • Arbutus Biopharma
  • Benitec Biopharma
  • OliX Pharmaceuticals
  • Atalanta Therapeutics

• Alnylam Pharmaceuticals

Alnylam is a pioneer in RNAi therapeutics and holds the first FDA approvals in the field, including givosiran. Its proprietary GalNAc delivery platform enables targeted liver delivery, supporting a strong pipeline for rare genetic and hepatic diseases.

• Novo Nordisk

Through its acquisition of Dicerna Pharmaceuticals, Novo Nordisk has expanded into RNAi therapeutics, focusing on cardiometabolic and endocrine disorders. The company leverages Dicerna’s GalXC platform to develop RNAi candidates that complement its existing diabetes and obesity treatment portfolio.

• Novartis

Novartis is advancing RNAi-based therapies primarily through its partnership with Alnylam on inclisiran, a siRNA therapy for lowering LDL cholesterol. Its USP lies in integrating RNAi with large-scale commercialization and cardiovascular expertise to deliver long-acting, infrequent-dosing solutions.

RNA Interference Therapeutics Industry News

• In November 2025, Arrowhead Pharmaceuticals announced the FDA approval of REDEMPLO (plozasiran), an innovative RNAi therapeutic designed to reduce triglyceride levels in adults with Familial Chylomicronemia Syndrome (FCS). The approval marked a significant advancement in RNAi-based treatments targeting rare lipid metabolism disorders and cardiovascular risk management.
• In March 2025, Sanofi launched Qfitlia, an innovative RNAi therapeutic for the treatment of hemophilia A and B. The U.S. FDA approval of Qfitlia marked a significant advancement in gene-silencing therapies for bleeding disorders and expanded the clinical applications of siRNA-based therapeutics.
• In March 2025, Alnylam Pharmaceuticals received U.S. FDA approval for Amvuttra for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The approval marked a major advancement in RNA interference (RNAi) therapeutics by expanding the use of gene-silencing therapies into cardiovascular indications and strengthening treatment options for patients with ATTR-related cardiomyopathy.
• In July 2024, Sirnaomics entered in a partnership with Gore Range Capital LLC to advance RNAi therapies specifically for aesthetic medicine. This collaboration will explore novel RNAi applications in skin rejuvenation and other cosmetic treatments.
• In September 2022, Alnylam Pharmaceuticals received approval from the European Commission to market AMVUTTRA. This RNAi therapy targets hereditary transthyretin-mediated (hATTR) polyneuropathy and offers a major treatment breakthrough for adults with this rare condition.

The RNA interference therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Indication

• Hereditary transthyretin-mediated amyloidosis (hATTR)
• Transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
• Acute hepatic porphyria (AHP)
• Primary hyperoxaluria type 1 (PH1)
• Hypercholesterolemia / Dyslipidemia
• Familial chylomicronemia syndrome (FCS)
• Hemophilia A and B

Market, By Route of Administration

• Subcutaneous (SC)
• Intravenous (IV)

Market, By End Use

• Hospitals 
• Specialty treatment centers
• Clinics

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Rest of the world